~~<i id='2B09FBA38D'><strike id='2B09FBA38D'><tt id='2B09FBA38D'><pre id='2B09FBA38D'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

comprehensive

author：fashion 2025-09-30 18:35:00 - browse：1

Eli Lilly said Friday that it will acquire Dermira, a small biotech developing drugs for chronic skin conditions, for $1.1 billion.

The centerpiece of the deal is the Dermira drug called lebrikizumab that aims to treat people suffering from moderate-to-severe atopic dermatitis, the most common form of eczema, a disease characterized by inflamed, itchy, and scaly skin.

Phase 3 clinical trials of lebrikizumab in atopic dermatitis are underway. If successful, the drug could compete against Dupixent, which has grown into a commercial blockbuster for Regeneron Pharmaceuticals and Sanofi.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Hospital price transparency does save money, advocate argues

entertainment

hotspot

explore

entertainment

hotspot

PabloMartinezMonsivais/APYou’rereadingthewebversionofHealthCareInc., STAT’sweeklynewsletter followin

WSS

Dewpoint Therapeutics lays off staff after losing partnerships

STAT Summit: How a Chicago ER doctor tackles gun violence

STAT Readout Newsletter: Today's biggest biotech updates

Test for long Covid? Researchers find new clue in blood samples

Biotech venture capitalists face new demands from investors

Think you might have Covid

hotspot

comprehensive

entertainment

State Dept. review finds Biden bears some blame for Afghanistan failures

STAT Summit: Michael J. Fox on progress in Parkinson's research

In age of alternative facts, a scholarly course on calling out crap

2023 STAT Wunderkinds: get to know the winners

Guidelines to prevent youth baseball injuries need more muscle

Pharmacists can make shortage drugs, but at what cost?

Tori Bowie and the unacceptable rates of Black maternal death

STAT Readout Newsletter: Today's biggest biotech updates

In Memoriam: Notable people who died in 2023

STAT Summit: Biotech founders on deal

hotspot

Research misconduct: Proposed new rules face resistance

Studies point to risks of excluding people with obesity from drug trials

Prior authorization will have to move faster under new Biden rule

NIH director takes cautious approach to Biden drug pricing priority

eGenesis tests gene

Medicare reduced heart disease by changing how it pays doctors

explore

entertainment

hotspot

hotspot